Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-interleukin 1 beta monoclonal antibody FL-101

A monoclonal antibody targeting the human proinflammatory cytokine interleukin-1 beta (IL-1b), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, anti-IL-1b monoclonal antibody FL-101 targets and binds to IL-1b and prevents the binding of IL-1b to the IL-1 receptor. This inhibits IL-1b-mediated signaling pathways, and suppresses inflammatory responses, tumorigenesis and angiogenesis mediated by IL-1b. IL-1b plays a key role in inflammation, which is present in various disease states including cancers. IL-1b-mediated signaling pathways include MAPK, cyclooxygenase and nuclear factor kappa B (NF-kB) pathways, which may lead to macrophage activation, intra-tumoral accumulation of immunosuppressive myeloid cells, and tumor growth, invasiveness, metastasis, and angiogenesis.
Synonym:anti-IL-1 beta monoclonal antibody FL-101
anti-IL-1b monoclonal antibody FL-101
anti-interleukin-1beta monoclonal antibody FL-101
Code name:FL 101
FL-101
FL101
Search NCI's Drug Dictionary